Compare Indofarma Tbk. (INAF) vs Medela Potentia Tbk. (MDLA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Indofarma Tbk. vs Medela Potentia Tbk. — how do they compare? Indofarma Tbk. trades at Rp126 (market cap 390.51B), while Medela Potentia Tbk. trades at Rp208 (market cap 2.91T, 5.49M 24h volume). The key difference: Medela Potentia Tbk. is far larger — about 7.5× Indofarma Tbk.'s market cap. Which is the better fit depends on your goals.
| INAF | MDLA | |
|---|---|---|
Market Cap | 390.51B | 2.91T |
Volume | — | 5.49M |
Lot | — | 54.88K |
Turnover | — | 1.14B |
Average Price | — | 208.24 |
Value | — | 1.14B |
Indicative Equilibrium Price | — | 208 |
Indicative Equilibrium Volume | — | 50 |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Indofarma Tbk.
PT Indonesia Farma Tbk, known as PT Indofarma (Persero) Tbk (the Company) was established based on Deed No. 1 dated January 2, 1996 as amended by Deed No. 134 dated January 26, 1996 both of Notary Sutjipto, SH. PT. Indofarma, Tbk began as medicine factory well known as "Pabrik Obat Manggarai". Then take over by Japan's Government from Nederland's Government on 1942. On 1950 the Indonesian Government acquisited the factory by Department of Health and functioned as center of pharmacy production for its department. On 1979 the name changed to be Department of Health Center of Pharmacy Production as non Profit institution as main assignment to produced medicine for public service. Then the Company changed the name as PT. Indonesia Farma Tbk, known as PT Indofarma (Persero) Tbk.
Read more on INAF →About Medela Potentia Tbk.
PT Medela Potentia Tbk. (Company) was established based on Deed of Establishment No. 04 dated August 5, 2011, of Public Notary Evy Ferdiana, S.H, Notary of Bekasi Regency, domiciled in Lemah Abang. The Company started its operation activities in 2013.
Read more on MDLA →
